RxDoctor Payments DataLook up a doctor →

Patrick Spencer, DO

Ophthalmology · Dayton, OHNPI 1861494304

Payments from drug & device makers

$470,921in general payments, 2019–2025

Across 305 payments — averaging $1544.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$444K
  • AbbVie$16K
  • Alcon$3K
  • Amgen$1K
  • Regeneron Healthcare Solutions, Inc.$574
  • Bausch & Lomb Americas Inc.$553
  • plus $5K from 30 others

What the payments were for

  • Food & beverage$13,348100%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$470,921 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$158,261
Medicare patients
276
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine88$96,829
LumiganBimatoprost90$42,511
RocklatanNetarsudil Mesylat/Latanoprost91$37,818
XiidraLifitegrast13$21,516
SimbrinzaBrinzolamide/Brimonidine Tart66$20,378
CombiganBrimonidine Tartrate/Timolol54$17,144
Prednisolone Acetate499$11,664
Brimonidine Tartrate181$9,575
Alphagan PBrimonidine Tartrate25$7,995
RhopressaNetarsudil Mesylate18$7,354
Ketorolac Tromethamine398$7,303
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol60$6,858
VyzultaLatanoprostene Bunod11$4,578
Latanoprost618$4,533
Cyclosporine11$4,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$16,243$164,478257 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$319$45,172109 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$553$26,09424 claims
AlconSimbrinza$3,384$20,37866 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate$35$6,09926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →